We are thrilled to announce that Fabrice Balavoine, PhD, MBA, has joined NEBULA. Fabrice brings over 20 years of leadership in innovative startups and deep expertise in drug discovery and pharmaceutical development. In his new role, he will drive NEBULA’s commercial growth by securing strategic partnerships with leading pharmaceutical companies.
Education & Expertise
- Engineering Degree from ESPCI Paris
- PhD in Organic Chemistry from Université Paris-Sud
- Executive MBA from ESSEC & Mannheim Business School
Proven Track Record
Throughout his career, Fabrice has:
- Established strategic collaborations from early-stage virtual and pharmacological screening through Phase III clinical trials
- Contributed to the growth and funding success of multiple biotech ventures
- Led pivotal licensing agreements in the biopharmaceutical sector
Previous Leadership Roles
- Director of R&D & Business Development
Quantum Genomics — focused on innovative cardiovascular treatments - CEO & Co-founder
Galactis Pharma — spearheaded development and successful exit of peptide-based CNS disorder therapies
What Fabrice Will Do at NEBULA
At NEBULA, Fabrice’s strategic vision and operational excellence will be instrumental in advancing our physics-based generative AI platform, enabling us to explore and map the complete 3D structural landscape of therapeutic targets.
Join us in welcoming Fabrice Balavoine to the NEBULA team and read the full announcement on LinkedIn.
What We Do at NEBULA
At NEBULA, we leverage physics-based, dataset-free generative AI to map the complete 3D structural landscape of dynamic therapeutic targets. By partnering with leading pharmaceutical companies, we accelerate AI-driven drug discovery, secure strategic pharma collaborations, and uncover novel binding sites for breakthrough therapies.
Leave a Reply